Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany

Journal of Medical Economics

Volumn 15, Issue 5, 2012, Pages 906-917

  Westerhout, K Y ^a   Verheggen, B G ^a   Schreder, C H ^b   Augustin, M ^c  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b Stallergenes GmbH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cost effectiveness; Grass pollen; Immunotherapy; OA; Rhinoconjunctivitis; Symptomatic medication

Indexed keywords

ALK DEPOT; BUDESONIDE; GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; LORATADINE; ORALAIR; PLACEBO; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ARTICLE; BURNING SENSATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; GERMANY; GRASS POLLEN; HAY FEVER; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; IMMUNOTHERAPY; INFLAMMATION; META ANALYSIS; PALLIATIVE THERAPY; POLLEN ALLERGY; PRURITUS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN IRRITATION; SKIN TINGLING; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SWELLING; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; ANTIGENS, PLANT; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; GERMANY; HUMANS; POACEAE; POLLEN; QUALITY-ADJUSTED LIFE YEARS; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 84865250509     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.688904     Document Type: Article

References (11)

1. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
2. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. Jan;123:160-166
3. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006 Apr; 117(4):802-9.
4. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
5. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006 Feb; 61(2):185-90.
6. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009 Jan; 123(1):167-173.e7
7. Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial. J Allergy Clin Immunol. 2001 Jan; 107(1):87-93.
8. Frew AJ, Powell RJ, Corrigan CJ, et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006 Feb;117(2):319-25.
9. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 updated September 2009. The Cochrane Collaboration, 2009. Available at: www.cochrane-handbook.org. Last accessed January 2011
10. Sutton AJ, Abrams KR, Jones DR, et al. Methods for Meta-Analysis in Medical Research. London: John Wiley 2000
11. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-Analysis. Statist. Med. 2002; 21:1539-1558